Jean-Paul Bahary

Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology

JCO Precision Oncology 2024cited by 16position: middledoi

Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424

International Journal of Radiation Oncology*Biology*Physics 2020cited by 57position: middledoi

Association of<i>MGMT</i>Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide

JAMA Oncology 2018cited by 201position: middledoi

Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics 2018cited by 75position: middledoi

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial

The Lancet Oncology 2017cited by 1,176position: middledoi

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

New England Journal of Medicine 2017cited by 656position: middledoi

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

New England Journal of Medicine 2016cited by 1,032position: middledoi

Ki-67 Is an Independent Predictor of Metastasis and Cause-Specific Mortality for Prostate Cancer Patients Treated on Radiation Therapy Oncology Group (RTOG) 94-08

International Journal of Radiation Oncology*Biology*Physics 2013cited by 46position: middledoi

No grants ingested yet.

Stephanie L. Pugh · NRG Oncology4 papers (2016–2020)Barbara J. Fisher · Rush University Medical Center3 papers (2016–2020)Minesh P. Mehta · Carbon Engineering (Canada)3 papers (2016–2020)Howard M. Sandler · Samueli Institute3 papers (2017–2024)Nadia N. Laack · Mayo Clinic3 papers (2017–2020)Christopher J. Schultz · University of North Carolina at Charlotte2 papers (2016–2018)Glenn J. Lesser · Virginia Commonwealth University2 papers (2018–2020)Felix Y. Feng · Polytechnique Montréal2 papers (2017–2024)Jan C. Buckner · Mayo Clinic in Arizona2 papers (2016–2017)Ya-Yu Tsai · Nanchang University2 papers (2018–2020)Young Kwok · University of Maryland, College Park2 papers (2018–2020)C.A. Lawton · Medical College of Wisconsin2 papers (2017–2018)Minhee Won · American College of Radiology2 papers (2016–2020)Paul D. Brown · Radiation Oncology Associates2 papers (2016–2017)Himanshu Lukka · McMaster University2 papers (2017–2018)Erica H. Bell · Neurosciences Institute2 papers (2016–2018)Kenneth L. Zeitzer · Indiana University – Purdue University Indianapolis2 papers (2013–2017)Maria Werner‐Wasik · Brown University2 papers (2018–2020)Arnab Chakravarti · The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute2 papers (2016–2018)Denise Fabian · University of Kentucky1 papers (2018–2018)

Recent publications

Grants

Frequent collaborators